Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: A retrospective cohort study

Clinical Therapeutics

Volumn 36, Issue 8, 2014, Pages

  Wu, Ning ^a   Lee, Yuan Chi ^a,c   Shah, Neel ^b   Harrison, David J ^b  

^a EVIDERA   (United States)

^b AMGEN INC   (United States)

^c LA Care Health Plan   (United States)

Author keywords

biologic response modifiers; cost; immune mediated inflammatory disease; pharmacy benefit manager; tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ANTIPSORIASIS AGENT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; COHORT ANALYSIS; DRUG COST; DRUG INDICATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; PHARMACY BENEFIT MANAGER; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; ADOLESCENT; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; ECONOMICS; HEALTH INSURANCE; IMMUNOLOGY; INSURANCE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ABATACEPT; ADALIMUMAB; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CERTOLIZUMAB PEGOL; DRUG COSTS; ETANERCEPT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITUXIMAB; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; UNITED STATES; USTEKINUMAB; YOUNG ADULT;

EID: 84906933655     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.014     Document Type: Article

References (24)

1. A. Kuek, B.L. Hazleman, and A.J. Ostor Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Postgrad Med J 83 2007 251 260
2. Enbrel (etanercept) [prescribing information]. lmmunex Corporation, Thousand Oaks, CA.
3. Orencia (abatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb.
4. Humira (adalimumab) [prescribing information]. Abbott Park, Ill: Abbott Laboratories.
5. Cimzia (certolizumab) [prescribing information]. Smyrna, Ga: UCB Inc.
6. Simponi (golimumab) [prescribing information]. Horsham, Pa: Janssen Biotech Inc.
7. Remicade (infliximab) [prescribing information]. Malvern, Pa: Centocor Inc.
8. Rituxan (rituximab) [prescribing information]. South San Francisco, Calif: Genentech Inc.
9. Stelara (ustekinumab) [prescribing information]. Horsham, Pa: Janssen Biotech Inc.
10. D.J. Harrison, X. Huang, and D. Globe Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis Am J Health Syst Pharm 67 2010 1281 1287
11. X. Huang, N.Y. Gu, and K.M. Fox et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice Curr Med Res Opin 26 2010 1637 1645
12. K.E. Donahue, D.E. Jonas, and R.A. Hansen et al. Drug therapy for rheumatoid arthritis in adults: an update. Comparative effectiveness review no. 55. Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I 2012 Agency for Healthcare Research and Quality Rockville, Md
13. K.E. Donahue, D.E. Jonas, and R.A. Hansen et al. Drug therapy for psoriatic arthritis in adults: update of a 2007 report. Comparative effectiveness review no. 54. Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I 2007 Agency for Healthcare Research and Quality Rockville, Md
14. V.F. Schabert, C. Watson, and S.R. Gandra et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States J Med Econ 15 2012 264 275
15. M. Bonafede, G.J. Joseph, N. Princic, and D.J. Harrison Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis J Med Econ 16 2013 1120 1128
16. D.A. Ollendorf, D. Klingman, E. Hazard, and S. Ray Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population Clin Ther 31 2009 825 835
17. D. Weycker, E.B. Yu, J.M. Woolley, and G. Oster Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis Clin Ther 27 2005 646 656
18. Pharmacy Benefit Managers. Prescription policy choices. http://www.policychoices.org/pharmacy-benefit-managers.shtml. Accessed April 9, 2013.
19. K.A. Look, D.A. Mott, and D.H. Kreling et al. Economic impact of pharmacist-reimbursed drug therapy modification J Am Pharm Assoc (2003) 51 2011 58 64
20. T.D. Gilbert Jr, D. Smith, and D.A. Ollendorf Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study BMC Musculoskelet Disord 5 2004 36
21. C.T. Carter, A.K. Changolkar, and R. Scott McKenzie Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients J Med Econ 15 2012 332 339
22. E. Wu, L. Chen, and H. Birnbaum et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data Curr Med Res Opin 23 2007 1749 1759
23. M.M. Bonafede, S.R. Gandra, and C. Watson et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis Adv Ther 29 2012 234 248
24. E.R. Cox, A. Kulkarni, and R. Henderson Impact of patient and plan design factors on switching to preferred statin therapy Ann Pharmacother 41 2007 1946 1953